Document is current

Article History

Accepted: 15 May 2025

First Online: 13 June 2025

Change Date: 9 July 2025

Change Type: Update

Change Details: In the version of the article initially published, in the “Test performance” column of the “JINLING (NCT06011694; ongoing)” row of Table 1, the stage I sensitivity was incorrectly listed as “62.5%” and has now been amended to “47.6%” in the HTML and PDF versions of the article.

Competing interests

: J.C.M.W. and N.R. are inventors on patents for methods of circulating tumour DNA detection. J.C.M.W. is a consultant for, co-founder and shareholder of Prima Mente and has been a consultant for Cleary Gottlieb, Delfi Diagnostics and Rostrum. P.S. is compensated by Grail for time spent on their advisory board and is also Director of the Cancer Prevention Trials Unit at Queen Mary University of London, which is contracted by GRAIL to act as the clinical trials unit for the NHS-Galleri trial.